Celldex Therapeutics Stock Price, News & Analysis (NASDAQ:CLDX)

$2.91 0.06 (2.11 %)
(As of 11/20/2017 04:28 AM ET)
Previous Close$2.85
Today's Range$2.84 - $3.00
52-Week Range$2.20 - $4.91
Volume1.76 million shs
Average Volume1.71 million shs
Market Capitalization$395.72 million
P/E RatioN/A
Dividend YieldN/A
Beta2.63

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:CLDX
  • CUSIP: 15117B10
  • Web: www.celldextherapeutics.com
Debt:
  • Current Ratio: 5.91%
  • Quick Ratio: 5.91%
Sales & Book Value:
  • Annual Sales: $6.79 million
  • Price / Sales: 58.28
  • Book Value: $2.17 per share
  • Price / Book: 1.34
Profitability:
  • Trailing EPS: ($1.01)
  • Net Income: ($128,530,000.00)
  • Net Margins: -1,088.58%
  • Return on Equity: -46.94%
  • Return on Assets: -32.11%
Misc:
  • Employees: 210
  • Outstanding Shares: 135,990,000
 

Frequently Asked Questions for Celldex Therapeutics (NASDAQ:CLDX)

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.07. The biopharmaceutical company earned $3.90 million during the quarter, compared to analysts' expectations of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The firm's revenue for the quarter was up 77.3% on a year-over-year basis. During the same period last year, the firm earned ($0.29) EPS. View Celldex Therapeutics' Earnings History.

Where is Celldex Therapeutics' stock going? Where will Celldex Therapeutics' stock price be in 2017?

5 brokerages have issued 1-year price targets for Celldex Therapeutics' shares. Their forecasts range from $3.50 to $10.00. On average, they anticipate Celldex Therapeutics' stock price to reach $7.50 in the next twelve months. View Analyst Ratings for Celldex Therapeutics.

What are Wall Street analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

  • 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer.  Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
  • 2. Cowen and Company analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)
  • 3. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)

Who are some of Celldex Therapeutics' key competitors?

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:

  • Larry Ellberger, Independent Chairman of the Board (Age 69)
  • Anthony S. Marucci, President, Chief Executive Officer, Director (Age 55)
  • Sam Martin, Chief Financial Officer, Senior Vice President (Age 46)
  • Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer (Age 58)
  • Sarah Cavanaugh, Senior Vice President - Corporate Affairs and Administration (Age 42)
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer (Age 45)
  • Margo Heath-Chiozzi, Senior Vice President - Regulatory Affairs (Age 60)
  • Theresa M. LaVallee Ph.D., , Senior Vice President - Regulatory and Precision Medicine (Age 50)
  • Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer (Age 61)
  • Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer` (Age 53)

Who owns Celldex Therapeutics stock?

Celldex Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Meditor Group Ltd (4.92%), Dimensional Fund Advisors LP (0.63%), Bank of New York Mellon Corp (0.48%), Schwab Charles Investment Management Inc. (0.42%), Ameriprise Financial Inc. (0.34%) and Russell Investments Group Ltd. (0.27%). Company insiders that own Celldex Therapeutics stock include Avery W Catlin and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.

Who sold Celldex Therapeutics stock? Who is selling Celldex Therapeutics stock?

Celldex Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Canada Pension Plan Investment Board, Oppenheimer & Co. Inc., Schwab Charles Investment Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for Celldex Therapeutics.

Who bought Celldex Therapeutics stock? Who is buying Celldex Therapeutics stock?

Celldex Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Russell Investments Group Ltd., Dynamic Technology Lab Private Ltd, Ameriprise Financial Inc., OxFORD Asset Management LLP, Cubist Systematic Strategies LLC, Dimensional Fund Advisors LP and Bank of New York Mellon Corp. View Insider Buying and Selling for Celldex Therapeutics.

How do I buy Celldex Therapeutics stock?

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of Celldex Therapeutics stock can currently be purchased for approximately $2.91.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $395.72 million and generates $6.79 million in revenue each year. The biopharmaceutical company earns ($128,530,000.00) in net income (profit) each year or ($1.01) on an earnings per share basis. Celldex Therapeutics employs 210 workers across the globe.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 Frontage Rd Ste 220, HAMPTON, NJ 08827-4034, United States. The biopharmaceutical company can be reached via phone at +1-908-2007500 or via email at [email protected]


MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  509
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Celldex Therapeutics (NASDAQ:CLDX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $7.50 (157.73% upside)

Consensus Price Target History for Celldex Therapeutics (NASDAQ:CLDX)

Price Target History for Celldex Therapeutics (NASDAQ:CLDX)

Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017HC WainwrightReiterated RatingBuyN/AView Rating Details
9/26/2017Cantor FitzgeraldReiterated RatingBuy$9.00LowView Rating Details
6/29/2017AegisReiterated RatingBuyMediumView Rating Details
6/6/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
5/11/2017Jefferies Group LLCReiterated RatingHold$4.00 -> $3.50HighView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$7.00N/AView Rating Details
11/8/2016WedbushReiterated RatingNeutral$3.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00N/AView Rating Details
3/7/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/7/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Celldex Therapeutics (NASDAQ:CLDX)

Earnings by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Earnings History by Quarter for Celldex Therapeutics (NASDAQ CLDX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.27)($0.20)$1.30 million$3.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.28)($0.23)$1.21 million$3.83 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.29)($0.28)$0.57 million$1.53 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.34)($0.30)$1.10 million$1.87 millionViewListenView Earnings Details
11/7/2016Q3 2016($0.33)($0.29)$1.09 million$2.20 millionViewN/AView Earnings Details
8/8/2016Q2($0.34)($0.32)$0.96 million$1.39 millionViewListenView Earnings Details
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details
11/5/2015Q3($0.35)($0.32)$1.02 million$1.03 millionViewN/AView Earnings Details
8/10/2015Q215($0.34)($0.33)$0.51 million$2.18 millionViewListenView Earnings Details
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details
11/4/2014Q3($0.33)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.31)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.26)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celldex Therapeutics (NASDAQ:CLDX)
2017 EPS Consensus Estimate: ($1.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.30)($0.26)($0.28)
Q2 20173($0.27)($0.23)($0.26)
Q3 20173($0.28)($0.20)($0.24)
Q4 20173($0.29)($0.20)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celldex Therapeutics (NASDAQ:CLDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celldex Therapeutics (NASDAQ CLDX)

Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 51.37%
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Insider Trades by Quarter for Celldex Therapeutics (NASDAQ CLDX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2016Tibor KelerVPBuy3,000$3.32$9,960.00View SEC Filing  
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.00View SEC Filing  
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.00View SEC Filing  
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.00View SEC Filing  
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.00View SEC Filing  
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View SEC Filing  
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celldex Therapeutics (NASDAQ CLDX)

Source:
DateHeadline
Celldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.20 Per ShareCelldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - November 19 at 5:08 PM
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous ... - GlobeNewswire (press release)Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous ... - GlobeNewswire (press release)
globenewswire.com - November 18 at 8:38 AM
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell CarcinomaCelldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
finance.yahoo.com - November 18 at 8:38 AM
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up - NasdaqCelldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up - Nasdaq
www.nasdaq.com - November 10 at 9:53 AM
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017
finance.yahoo.com - November 9 at 8:11 PM
Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 8:11 PM
Leerink Swann Analysts Raise Earnings Estimates for Celldex Therapeutics, Inc. (CLDX)Leerink Swann Analysts Raise Earnings Estimates for Celldex Therapeutics, Inc. (CLDX)
www.americanbankingnews.com - November 9 at 8:30 AM
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares UpCelldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
finance.yahoo.com - November 8 at 9:14 PM
ETFs with exposure to Celldex Therapeutics, Inc. : November 8, 2017ETFs with exposure to Celldex Therapeutics, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 9:14 PM
Celldex reports 3Q lossCelldex reports 3Q loss
finance.yahoo.com - November 7 at 8:16 PM
Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a NumberCelldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
finance.yahoo.com - November 7 at 8:16 PM
How Much Did Celldex Therapeutics Inc’s (CLDX) CEO Pocket Last Year?How Much Did Celldex Therapeutics Inc’s (CLDX) CEO Pocket Last Year?
finance.yahoo.com - November 7 at 8:16 PM
Celldex Therapeutics, Inc. (CLDX) Announces  Earnings ResultsCelldex Therapeutics, Inc. (CLDX) Announces Earnings Results
www.americanbankingnews.com - November 7 at 5:27 PM
Why Celldex Therapeutics Jumped Higher TodayWhy Celldex Therapeutics Jumped Higher Today
www.fool.com - November 7 at 2:41 PM
Why Celldex Therapeutics Stock Crumbled in OctoberWhy Celldex Therapeutics Stock Crumbled in October
www.fool.com - November 7 at 11:12 AM
Celldex Reports Third Quarter 2017 ResultsCelldex Reports Third Quarter 2017 Results
feeds.benzinga.com - November 7 at 8:26 AM
Is Celldex Therapeutics Inc (CLDX) Undervalued?Is Celldex Therapeutics Inc (CLDX) Undervalued?
finance.yahoo.com - November 6 at 6:30 PM
Celldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by AnalystsCelldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 2 at 5:48 PM
Celldex (CLDX) to Report Q3 Earnings: Whats in the Cards?Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
www.nasdaq.com - November 1 at 6:02 PM
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
finance.yahoo.com - November 1 at 6:02 PM
Zacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Announce Quarterly Sales of $1.17 MillionZacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Announce Quarterly Sales of $1.17 Million
www.americanbankingnews.com - November 1 at 2:46 PM
Celldex Therapeutics, Inc. (CLDX) to Release Earnings on MondayCelldex Therapeutics, Inc. (CLDX) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : October 26, 2017Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : October 26, 2017
finance.yahoo.com - October 26 at 5:32 PM
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 25, 2017Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 25, 2017
finance.yahoo.com - October 25 at 6:46 PM
Interesting CLDX Call Options For December 15thInteresting CLDX Call Options For December 15th
www.thestreet.com - October 24 at 7:37 PM
Celldex Therapeutics, Inc. (CLDX) Short Interest Down 42.3% in SeptemberCelldex Therapeutics, Inc. (CLDX) Short Interest Down 42.3% in September
www.americanbankingnews.com - October 13 at 1:32 AM
Short Interest Declines 42.3% For CLDXShort Interest Declines 42.3% For CLDX
www.thestreet.com - October 11 at 6:48 PM
Zacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per ShareZacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - October 11 at 2:08 AM
Celldex Therapeutics, Inc. (CLDX) Receives Consensus Recommendation of "Hold" from AnalystsCelldex Therapeutics, Inc. (CLDX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 8 at 2:44 PM
Whats Behind Celldex Therapeutics, Inc.s 16% Rally in September? - Motley FoolWhat's Behind Celldex Therapeutics, Inc.'s 16% Rally in September? - Motley Fool
www.fool.com - October 6 at 5:29 PM
What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
finance.yahoo.com - October 6 at 5:29 PM
Whats Behind Celldex Therapeutics, Inc.s 16% Rally in September?What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
www.fool.com - October 6 at 4:45 PM
Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory AffairsCelldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs
finance.yahoo.com - October 3 at 5:07 PM
ETFs with exposure to Celldex Therapeutics, Inc. : September 26, 2017ETFs with exposure to Celldex Therapeutics, Inc. : September 26, 2017
finance.yahoo.com - October 2 at 5:25 PM
How Does Investing In Celldex Therapeutics Inc (CLDX) Impact Your Portfolio?How Does Investing In Celldex Therapeutics Inc (CLDX) Impact Your Portfolio?
finance.yahoo.com - October 2 at 5:25 PM
Why Celldex Therapeutics Is A Buy (Part 2) - Seeking AlphaWhy Celldex Therapeutics Is A Buy (Part 2) - Seeking Alpha
seekingalpha.com - September 30 at 3:27 PM
Cantor Fitzgerald Reiterates Buy Rating for Celldex Therapeutics, Inc. (CLDX)Cantor Fitzgerald Reiterates Buy Rating for Celldex Therapeutics, Inc. (CLDX)
www.americanbankingnews.com - September 27 at 6:10 PM
Why Celldex Therapeutics, Inc. Jumped Higher TodayWhy Celldex Therapeutics, Inc. Jumped Higher Today
www.fool.com - September 25 at 4:29 PM
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 25, 2017Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 25, 2017
finance.yahoo.com - September 25 at 12:30 PM
Head-To-Head Contrast: Celldex Therapeutics (CLDX) and The CompetitionHead-To-Head Contrast: Celldex Therapeutics (CLDX) and The Competition
www.americanbankingnews.com - September 24 at 6:18 PM
Celldex Therapeutics, Inc. (CLDX) Expected to Announce Quarterly Sales of $1.17 MillionCelldex Therapeutics, Inc. (CLDX) Expected to Announce Quarterly Sales of $1.17 Million
www.americanbankingnews.com - September 24 at 3:44 AM
 Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per Share Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - September 22 at 12:14 PM
Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceCelldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 9:59 AM
Reasons Why Celldex Therapeutics Is A Buy (Part 1) - Seeking AlphaReasons Why Celldex Therapeutics Is A Buy (Part 1) - Seeking Alpha
seekingalpha.com - September 21 at 5:07 PM
Celldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by BrokeragesCelldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 13 at 4:46 PM
Celldex Announces Departure of Chief Medical Officer - GlobeNewswire (press release)Celldex Announces Departure of Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - September 13 at 3:55 AM
After-Hours Stock Movers 09/12: (SNAK) (JWN) (CNC) Higher; (AMRK) (TCMD) (CLDX) Lower (more...)After-Hours Stock Movers 09/12: (SNAK) (JWN) (CNC) Higher; (AMRK) (TCMD) (CLDX) Lower (more...)
www.streetinsider.com - September 12 at 10:53 PM
Celldex Announces Departure of Chief Medical OfficerCelldex Announces Departure of Chief Medical Officer
finance.yahoo.com - September 12 at 5:53 PM
ETFs with exposure to Celldex Therapeutics, Inc. : September 12, 2017ETFs with exposure to Celldex Therapeutics, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 10:57 PM
ETFs with exposure to Celldex Therapeutics, Inc. : August 31, 2017ETFs with exposure to Celldex Therapeutics, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:11 PM

Social Media

Financials

Chart

Celldex Therapeutics (NASDAQ CLDX) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.